Literature DB >> 17349016

Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses.

Y Wang1, Y Mei, S Bao, L Xu.   

Abstract

Vasoactive intestinal polypeptide (VIP) is an important signal molecule of the neuroendocrine-immune network. In the immune system, VIP has been found to act as an endogenous anti-inflammatory mediator. In the current study, it was found that VIP administration regulated oral tolerance by inhibiting both cellular and humoral responses. Compared with vehicle-treated mice, mice treated with VIP during the development of ovalbumin (OVA)-induced oral tolerance exhibited the least delayed-type hypersensitivity (DTH), showed profoundly reduced proliferative capacity and produced less interferon (IFN)-gamma, interleukin (IL)-6, IL-5, IL-10 and interferon-inducible protein (IP-10). IgA-secreting cells in the gut as well as OVA-specific IgG and other isotypes levels in plasma were inhibited significantly after VIP-treatment. The VPAC2 receptor may be involved in VIP-mediated oral tolerance enhancement. Taken together, these results suggest that VIP enhanced oral tolerance via regulating both cellular and humoral responses.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17349016      PMCID： PMC1868860          DOI： 10.1111/j.1365-2249.2007.03322.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  47 in total

1.  Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma.

Authors:  H B Kaltreider; S Ichikawa; P K Byrd; D A Ingram; J L Kishiyama; S P Sreedharan; M L Warnock; J M Beck; E J Goetzl
Journal:  Am J Respir Cell Mol Biol       Date:  1997-02       Impact factor: 6.914

2.  Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice.

Authors:  M N Kweon; K Fujihashi; J L VanCott; K Higuchi; M Yamamoto; J R McGhee; H Kiyono
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene.

Authors:  S P Sreedharan; J X Huang; M C Cheung; E J Goetzl
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

4.  Occurrence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse.

Authors:  R P Gomariz; M De La Fuente; A Hernanz; J Leceta
Journal:  Ann N Y Acad Sci       Date:  1992-04-15       Impact factor: 5.691

5.  VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells.

Authors:  K Maruno; A Absood; S I Said
Journal:  Am J Physiol       Date:  1995-06

6.  Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.

Authors:  M Delgado; C Martinez; M C Johnson; R P Gomariz; D Ganea
Journal:  J Neuroimmunol       Date:  1996-08       Impact factor: 3.478

7.  Induction of anergy or active suppression following oral tolerance is determined by antigen dosage.

Authors:  A Friedman; H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Peripheral deletion of antigen-reactive T cells in oral tolerance.

Authors:  Y Chen; J Inobe; R Marks; P Gonnella; V K Kuchroo; H L Weiner
Journal:  Nature       Date:  1995-07-13       Impact factor: 49.962

9.  Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis.

Authors:  Y Chen; V K Kuchroo; J Inobe; D A Hafler; H L Weiner
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

10.  Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues.

Authors:  J Xu-Amano; H Kiyono; R J Jackson; H F Staats; K Fujihashi; P D Burrows; C O Elson; S Pillai; J R McGhee
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307
View more
  7 in total

1.  Oral gene application using chitosan-DNA nanoparticles induces transferable tolerance.

Authors:  Katja Goldmann; Stephan M Ensminger; Bernd M Spriewald
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

2.  The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.

Authors:  Chaneun Nam; Adam J Case; Bruce S Hostager; M Sue O'Dorisio
Journal:  J Mol Neurosci       Date:  2008-07-29       Impact factor: 3.444

Review 3.  Allergy and the gastrointestinal system.

Authors:  G Vighi; F Marcucci; L Sensi; G Di Cara; F Frati
Journal:  Clin Exp Immunol       Date:  2008-09       Impact factor: 4.330

4.  Maternal atopy and offspring epigenome-wide methylation signature.

Authors:  Hanna Danielewicz; Artur Gurgul; Anna Dębińska; Grzegorz Myszczyszyn; Tomasz Szmatoła; Anna Myszkal; Igor Jasielczuk; Anna Drabik-Chamerska; Lidia Hirnle; Andrzej Boznański
Journal:  Epigenetics       Date:  2020-09-09       Impact factor: 4.528

5.  VIP Regulates the Development & Proliferation of Treg in vivo in spleen.

Authors:  Anthony M Szema; Sayyed A Hamidi; Marc G Golightly; Todd P Rueb; John J Chen
Journal:  Allergy Asthma Clin Immunol       Date:  2011-11-29       Impact factor: 3.406

6.  Glycoprotein A33 deficiency: a new mouse model of impaired intestinal epithelial barrier function and inflammatory disease.

Authors:  Benjamin B Williams; Niall C Tebbutt; Michael Buchert; Tracy L Putoczki; Karen Doggett; Shisan Bao; Cameron N Johnstone; Frederick Masson; Frederic Hollande; Antony W Burgess; Andrew M Scott; Matthias Ernst; Joan K Heath
Journal:  Dis Model Mech       Date:  2015-05-08       Impact factor: 5.758

7.  Neuropeptides and lymphocyte populations in the porcine ileum and ileocecal lymph nodes during postnatal life.

Authors:  Krzysztof Wasowicz; Anna Winnicka; Jerzy Kaleczyc; Michal Zalecki; Piotr Podlasz; Zenon Pidsudko
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.